Eli Lilly and Co’s Revenue by Segment

This statistic highlights Eli Lilly and Co’s Revenue by Segment, split between Animal Health Products and Human Pharmaceuticals, reported on a quarterly basis from Q1 2016 onwards.

The company sells most of its products worldwide. It adapts its marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations. Their products are available in over 120 countries. The total Revenue of the company has been rising continuously since 2014. It experienced a little drag down in 2018 compared to 2017 but it has been rising significantly since 2018.  The company’s Revenue is further bifurcated into the following segments.

Eli Lilly and Co’s Revenue by Segment

(All figures are in billions, except percentage)

Eli Lilly & Corporation Revenue by Segment increases by YOY and QOQ basis. Earlier in Q4 2017 company holds a revenue of $12 billion while in next year Q4 2018 it jumped to $66 billion showing an increase of 450%. The company’s animal health products show revenue holding by 14% only while the rest of the revenue is coming from human pharmaceuticals is 86%.

However, there is a rise in quarterly business revenue also, in Q3 2018 animal health products hold $8 billion while next year shows a rise of 12.5% that changes the figure to $9 billion in Q3 2021, for human pharmaceuticals. Every year licensed animal health products to hold around 15% of the revenue other hand rest is held by human pharmaceuticals which is 0f 85%.

Animal Health Products

Animal Health Products are defined to include all the  pharmaceutical, biological and medicinal, including in feed, products that are intended to enhance the health or performance of any and all species of animals, including livestock and  the companion animals but excluding humans, but to exclude (i) any products with the different intended utility, (ii) the nutritional additives, (iii) the chemical intermediates,

The company shows immense up and down in revenue by segment in Animal Health Products. Earlier in 2017 company holds a total of $8 billion in Q4 2017, while in the year Q4 2018 it rises to $9 billion. This shows there 12.5% rise in revenue in this segment of the company.

Human Pharmaceuticals

Human Pharmaceuticals is a kind of  prescription medicine unit which focuses on various therapeutic areas. Through its info related to  Diabetes, Oncology, Cardiovascular and Respiratory portfolios, Boehringer Ingelheim MENA aims to bring solutions to the patients that will improve the quality of life. Stroke prevention and treatment is one of the main focus areas in the region, where hospitals aim at enhancing stroke management, raising awareness hoping at saving lives through innovative solutions.

The company shows immense up and down in revenue by segment in Human Pharmaceuticals. Earlier in 2017 company holds a total of $4 billion in Q4 2017, while in the year Q4 2018 it rises to $57 billion. This shows there 1325% rise in revenue in this segment of the company.

About the Company

Eli Lilly and Company was incorporated in 1901 in Indiana to succeed in the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. They specialize on one business segment: human pharmaceutical products, which they research, develop, manufacture, and market. In March 2019, they completed the disposition of their ownership in Elanco Animal Health Incorporated (Elanco), an animal health business.

Their purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products they sell today were discovered or developed by their scientists, and their long-term success depends on their ability to continually discover or acquire, develop, and commercialize innovative new medicines.

Did you like Eli Lilly and Co’s Revenue by Segment statistic?

Access more such key performance indicator (KPI) data points and segment financials, on thousands of US stocks, with Business Quant.

You can get started here.